Cargando…

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer

PURPOSE: Neoadjuvant chemotherapy is the standard treatment for patients with locally advanced breast cancer and is increasingly considered for patients with operable disease. Recently, as many clinical trials have demonstrated favorable outcomes of anthracycline-taxane based regimen, this approach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Woo Sung, Jeon, Ja Young, Kang, Seok Yun, Jung, Yong Sik, Kim, Ji Young, Ahn, Mi Sun, Kang, Doo Kyoung, Kim, Tae Hee, Yim, Hyun Ee, An, Young-Sil, Park, Rae Woong, Kim, Ku Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Surgical Society 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699689/ https://www.ncbi.nlm.nih.gov/pubmed/23833754 http://dx.doi.org/10.4174/jkss.2013.85.1.7

Ejemplares similares

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2015)

The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
por: Javan-Noughabi, Javad, et al.
Publicado: (2018)

Advanced Stage Is a Risk for Severe Neutropenia in Breast Cancer Patients Undergoing Neoadjuvant Adriamycin/Cyclophosphamide/Docetaxel Chemotherapy
por: Moro, Kazuki, et al.
Publicado: (2022)

Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
por: Mendoza-Posada, Daniel, et al.
Publicado: (2007)

Serial Assessment of Myocardial Properties Using Cyclic Variation of Integrated Backscatter in an Adriamycin-Induced Cardiomyopathy Rat Model
por: Ha, Jong-Won, et al.
Publicado: (2005)

Apoptosis and remodeling in adriamycin-induced cardiomyopathy rat model
por: Hong, Young Mi, et al.
Publicado: (2017)

Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy
por: Kim, Da Rae, et al.
Publicado: (2017)

Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.
por: Klugmann, F. B., et al.
Publicado: (1986)

Losartan Reduces Remodeling and Apoptosis in an Adriamycin-Induced Cardiomyopathy Rat Model
por: Kim, Hyeon A, et al.
Publicado: (2023)

Detection of Adriamycin–DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations
por: Coldwell, Kate E., et al.
Publicado: (2008)

Effects of the Combination of Gliotoxin and Adriamycin on the Adriamycin-Resistant Non-Small-Cell Lung Cancer A549 Cell Line
por: Manh Hung, Le Van, et al.
Publicado: (2018)

Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer: A case report
por: Jang, Lee Chan, et al.
Publicado: (2019)

Promising effects of 3rd line cyclophosphamide, adriamycin and vincristine (CAV) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer
por: Jung, Sang Ok, et al.
Publicado: (2015)

Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer
por: Qi, Min, et al.
Publicado: (2021)

Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy
por: Kim, Hyung Sook, et al.
Publicado: (2019)

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)

Cross-talk between ER stress and mitochondrial pathway mediated adriamycin-induced testicular toxicity and DA-9401 modulate adriamycin-induced apoptosis in Sprague–Dawley rats
por: Karna, Keshab Kumar, et al.
Publicado: (2019)

Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
por: Kondo, Yasuyuki, et al.
Publicado: (1995)

Adriamycin cardiotoxicity monitoring by radionuclide scan.
por: Robinson, B. A., et al.
Publicado: (1983)

Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
por: Berruti, A, et al.
Publicado: (1999)

Effects of Dietary Protein and Fat Contents on Renal Function and Inflammatory Cytokines in Rats with Adriamycin-Induced Nephrotic Syndrome
por: Kim, Su Yeon, et al.
Publicado: (2011)

Successful treatment of disseminated interdigitating dendritic cell sarcoma with adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy
por: Lee, Suk-young, et al.
Publicado: (2012)

Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
por: Hwang, Inhwan, et al.
Publicado: (2023)

Acute Induction of Adriamycin‐resistance in Human Colon Carcinoma HT‐29 Cells Exposed to a Sublethal Dose of Adriamycin
por: Tomida, Akihiro, et al.
Publicado: (1995)

Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells
por: Chen, Li, et al.
Publicado: (2019)

Value of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy
por: Kim, Tae Hee, et al.
Publicado: (2016)

The Role of Beetroot Extract in Overcoming Chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide Regimen by Targeting Immune Response in Tumor Microenvironment: A Preclinical Study in Mammary Adenocarcinoma Rats
por: Susilowati, Sri, et al.
Publicado: (2022)

Cytotoxicity of adriamycin to tumour cells in vivo and in vitro.
por: Martin, W. M., et al.
Publicado: (1980)

Different distribution of adriamycin in normal and leukaemic rats.
por: Sonneveld, P., et al.
Publicado: (1981)

A Sarcoma at the Site of Previous Extravasation of Adriamycin
por: Ceulemans, Joris, et al.
Publicado: (2002)

An in vivo assessment of adriamycin-loaded albumin microspheres.
por: Goldberg, J. A., et al.
Publicado: (1992)

Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats
por: Mansouri, Esrafil, et al.
Publicado: (2018)

Preventive role of carvedilol in adriamycin-induced cardiomyopathy
por: Jhorawat, Rajesh, et al.
Publicado: (2016)

Adriamycin does not damage podocytes of zebrafish larvae
por: Schindler, Maximilian, et al.
Publicado: (2020)

Renoprotective Effects of a Highly Selective A3 Adenosine Receptor Antagonist in a Mouse Model of Adriamycin-induced Nephropathy
por: Min, Hye Sook, et al.
Publicado: (2016)

Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
por: Pereira-Oliveira, Maria, et al.
Publicado: (2019)

TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells
por: Chen, Li, et al.
Publicado: (2019)

Chemosensitization to adriamycin by cyclosporin A and verapamil in human retinoblastoma cell lines.
por: Lee, T. W., et al.
Publicado: (1993)

Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
por: Kim, Se Hyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fock0mr7mc4joocec9up6k6dh7